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Can we today apply genetics to individual patients and tailor
therapy based on genetic profile to improve pharmacody-
namics and kinetics [1]? This is an interesting question
especially for the treatment of hypertension as substantial
heterogeneity in efficacy exists in response to drug therapy.
Individualised medicine may guide physicians in their
choice instead of the old-fashioned trial-and-error strategy
to find the perfect cocktail of antihypertensive drugs. In
addition, tailored therapy may lead to fewer adverse drug
reactions and eventually to a lower burden on health care
costs [2]. Although the department of cardiology of the
University Medical Center Utrecht is committed to the
integration of genetics into clinical medicine, we do not
determine a genetic profile in patients on a routine basis
[3]. Especially not before prescribing a drug in the clinic
or in the outpatient department. But maybe it is time to
change our attitude and integrate genetics into daily
clinical practice. Nowadays it is technically feasible to
determine several single nucleotide polymorphisms
(SNPs) within 1 hour at relatively low costs in the outpatient
office without the need for specialised laboratory facilities
[4, 5].
In their review article in this issue of the Netherlands
Heart Journal, Brugts et al. suggest that we should adjust
our current practice. The review contains a broad description
of the role of ACE inhibition in the treatment of patients
with atherosclerosis [6]. The paper is very well written
and comprises part of the outstanding work delivered by the
Rotterdam group and collected in the thesis successfully
defended by Dr Brugts. Here the focus is on genetic analysis.
In a substudy of the well-described EUROPA trial with
9454 patients suffering from stable coronary artery disease, a
genetic analysis was performed (PERGENE study) [7]. After
multivariate analysis 3 SNPs were reported to be related to
the effect of perindopril on cardiovascular events. Patients
with 3 or more unfavourable alleles were considered to be
nonresponders based on numbers of events. This paper
suggests to decide on the treatment with ACE inhibitors
based on genetic profiling. The authors claim that one
out of 4 patients should not be treated with ACE inhib-
itors to reduce the cost of treatment and to improve drug
efficacy [8].
The question is whether there is now sufficient proof that
genetic testing is important for decision-making and if so
can we apply the statistics of the large population to one
individual. Several issues with respect to the PERGENE
study catch the eye. Looking at figure 5 in their article, it
is crucial to realise that the most important variation is in the
placebo group and not so much in the treated group [6]. The
variation in the ACE inhibitor treated group varies from 8.0,
7.5 to 9.4 and is very modest. The real variation is found in
the placebo group. Here the absolute risk moves from 10.2
to 11.1 and 7.7. Basically, the PERGENE study does not say
much about the effect of ACE inhibitor therapy, but more on
basic risk without additional treatment to develop events. If
the risk is modest ACE inhibition does not add much. In
addition, as the authors stated, sample size is an issue in
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subgroup analyses. Unfortunately, no similar randomised
trial to EUROPA with available DNA samples exists at this
point, thereby eliminating the possibility to replicate or
increase the sample size. Another issue is the coverage of
the genes by tagSNPs. It is not likely that the selected SNPs
are biologically relevant considering their high frequency,
but serve as proxy for the functional variant. Those
variants are rare and are not well covered by traditional
genome-wide association studies. Resequencing of all
genes within the RAAS and bradykinin system will be
neededtodetectfunctionalvariantsexplaininginterindividual
variability in drug response. All clinicians are aware of
the difficulty in translating statistically significant epide-
miological and also genetic data to the treatment of one
individual [9]. This is especially true for subtle changes
i nr i s kr e l a t e dt oaf e wS N P s .B a s e do ne p i d e m i o l o g y ,
oestrogen suppletion in postmenopausal women appeared
a logical next step in the 1990s [10]. Clinical trials
showed the downside of such an intervention. Therefore,
randomised clinical trials (RCT) randomising treatment
based on genetic profiling are necessary to provide a
definitive answer whether tailored therapy will improve
outcome. Trials using genotype-guided therapy, such as
RAPID GENE, are already underway for the treatment of
ACS patients. In this trial the ReAssessment of Anti-Platelet
Therapy Using an InDividualized Strategy Based on GENetic
Evaluation (RAPID GENE) will be performed to identify
CYP2C19*2 carriers. Carriers will be treated with prasugrel.
The study has been completed and the results are expected
soon.
In conclusion, pharmacogenetics are around the corner,
but need RCTs and improved bioinformatics before genetic
analysis will be crucial in every cardiology office to advice
our patients.
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